phaseic acid: a plant hormone derived from abscisic acid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5281527 |
| CHEMBL ID | 3594247 |
| CHEBI ID | 28205 |
| Synonym |
|---|
| CHEBI:28205 |
| (2z,4e)-5-[(1r,5r,8s)-8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo[3.2.1]oct-8-yl]-3-methylpenta-2,4-dienoic acid |
| (7e,9z)-(1r,5r,6s)-5,16-epoxy-6-hydroxy-3-oxo-5,6-dihydro-11-apo-beta-caroten-11-oic acid |
| (-)-phaseic acid |
| 24394-14-7 |
| phaseic acid |
| C09707 |
| (2z,4e)-5-[(1r,5r,8s)-8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo[3.2.1]octan-8-yl]-3-methylpenta-2,4-dienoic acid |
| CHEMBL3594247 |
| Q7180977 |
| MS-23977 |
| 2,4-pentadienoic acid, 5-((1r,5r,8s)-8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo(3.2.1)oct-8-yl)-3-methyl-, (2z,4e)- |
| (-)-neophasic acid |
| (2z,4e)-5-((1r,5r,8s)-8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo(3.2.1)oct-8-yl)-3-methyl-2,4-pentadienoic acid |
| unii-yl2mmw26mj |
| 2,4-pentadienoic acid, 5-(8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo(3.2.1)oct-8-yl)-3-methyl-, (1r-(1alpha,5alpha,8s*(2z,4e)))- |
| 2,4-pentadienoic acid, 5-(8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo(3.2.1)oct-8-yl)-3-methyl- |
| yl2mmw26mj , |
| (2z,4e)-5-[(1r,5r,8s)-8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo[3.2.1]oct-8-yl]-3-methyl-2,4-pentadienoic acid |
| DTXSID801028483 |
| 2,4-pentadienoic acid, 5-(8-hydroxy-1,5-dimethyl-3-oxo-6-oxabicyclo(3.2.1)oct-8-yl)-3-methyl-, (1r-(1.alpha.,5.alpha.,8s*(2z,4e)))- |
| CS-0094770 |
| HY-111973 |
phaseic acid (PA) is a phytohormone regulating important physiological functions in higher plants.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Phaseic acid (PA) is a phytohormone regulating important physiological functions in higher plants. " | ( Phaseic Acid, an Endogenous and Reversible Inhibitor of Glutamate Receptors in Mouse Brain. Abrams, SR; Benson, CL; Han, X; Hou, ST; Jiang, SX; Slinn, J; Zaharia, LI, 2016) | 3.32 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| apo carotenoid sesquiterpenoid | |
| alpha,beta-unsaturated monocarboxylic acid | A monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Abscisate degradation I | 0 | 9 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1235012 | Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID1235019 | Antiviral activity against Influenza A virus (A/FM/1/47(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID1235015 | Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||